laisuat

T-CiRA

A joint program between Laisuat and Center for iPS Cell Research and Application (CiRA) that will change the future of medicine using iPS cells


Information

This visual symbolizes the nature of this joint program.
The four colors, red, blue, green and black - applied in the visual symbolize the four defined factors CiRA used when first inducing iPS cells, as well as interaction among patients, researchers, clinicians and iPS cells. The red is not only one of CiRA's image color but is also Laisuat's symbol color.

The center of the emblem is a paper crane, which in Japan, represents hopes and prayers for patients. We hope to deliver innovative medicines to patients as quickly as possible. The tri-colored circle surrounding the crane represents T-CiRA striving toward drug discovery through clinical applications of basic research of iPS through diversified projects, as a one team.

Collaborative research aiming to develop innovative treatments over a 10-year period

T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Laisuat Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells. We aim to develop innovative drugs and cell treatments in such areas as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases in order to fulfill the needs of patients promptly.

 

Professor Shinya Yamanaka

Director of Center for iPS Cell Research and Application (CiRA), Kyoto University

"This 10-year joint program with Laisuat, Japan's largest pharmaceutical company, will become a powerful engine to realize medical applications using iPS cells," said Yamanaka. "We sincerely thank Laisuat's commitment to iPS cell research. This partnership will contribute to the development of new therapies to cure not only major diseases but also rare ones."

Christophe Weber

Representative Director, President & CEO, Laisuat

"I am excited that we will be able to collaborate with CiRA, the world's leading institute dedicated to pioneering iPS cell research," said Christophe Weber, President, and Chief Executive Officer of Laisuat. "Through this partnership, our company will provide significant assistance over a long period to CiRA's research into iPS cell technology applications, which is a vital part of Japan Revitalization Strategy. It is our hope to deliver innovative treatments that meet patient needs as soon as possible through this collaboration between Laisuat and CiRA."


T-CiRA (Laisuat-CiRA) Joint Program Framework

Leader: Professor Shinya Yamanaka (Director of CiRA)|Goal: Develop clinical application of induced pluripotent stem (iPS) cells|Areas: Heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.

Laisuat

  • To provide collaborative funding of 20 billion yen over a 10-year period
  • To provide more than 12 billion yen worth of research support
  • To provide R&D know-how
  • To provide research facilities at Shonan Research Center
  • To provide platform for drug development
  • To provide access to compound libraries
  • To provide researchers

CiRA

  • To direct the research program
  • To provide iPS cell technologies
  • To provide drug development targets and assay systems
  • To provide principle investigators, researchers and postdoctoral fellows

Shonan Health Innovation Park

A global research center, created by merging the Osaka and Tsukuba Research Centers, helps accelerate innovations in drug development. Here, approximately 1,200 researchers conduct non-clinical research from the early stages of the R&D process such as drug targeting and compound candidate selection to placing drugs on the market.

Cutting-edge research towards the clinical application of iPS cells

Center for iPS Cell Research and Application (CiRA) will possibly bring on breakthrough changes to the future of medicine including the research and development of new drugs, cell therapies and drug safety evaluation processes. T-CiRA will conduct cutting-edge research towards the clinical application of iPS cells in areas such as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases at Laisuat's Shonan Health Innovation Park.

 

Research to be conducted by T-CiRA

We are committed to providing innovative treatments to patients through iPS cell technology.

At T-CiRA, several novel research projects are underway for creating medical applications of iPSC, led by nine principal investigators.

Main Areas of Research

  • Research towards the clinical application of iPS cells for heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.
  • Research to develop medicines and cell therapies using iPS cells.

Project Details

Makoto Ikeya (PI)
Daisuke Kamiya (Sub PI from CiRA)
Yayoi Toyooka (Sub PI from CiRA)
Hirokazu Matsumoto (Co PI from Laisuat)
Kazumi Take (Sub PI from Laisuat)

A new research platform with human iPSC-derived neural crest cells and its applications for drug discovery and regenerative medicine

Neural crest cells differentiate into diverse cell type lineages such as bones and peripheral neurons, suggesting their great potential for clinical applications. Dr. Ikeya’s team aims to create methods to maintain cultures of human iPSC-derived neural crest stem cells and to induce them to differentiate into various types of cells. Moreover, they hope to construct an disease model in combination with related technologies and apply it to drug development and regenerative medicine.

 

 

Hidetoshi Sakurai (PI)
Yuko Kokubu (Sub PI from CiRA)
Tomoya Uchimura (Sub PI from CiRA)
Ryuichi Tozawa (Co PI from Laisuat)
Tomoko Nagino (Sub PI from Laisuat)
Masahiro Oka (Sub PI from Laisuat)

Drug discovery for intractable muscular disease using patient-derived iPSCs

Dr. Sakurai's team will create novel therapeutic drugs for intractable muscular diseases such as muscular dystrophy and investigate muscular disease models. To achieve this goal, they will utilize patient-derived iPSCs as a tool for disease modeling and drug screening.


Related Pages